Mullen Katelyn M, Hong Jungeui, Attiyeh Marc A, Hayashi Akimasa, Sakamoto Hitomi, Kohutek Zachary A, McIntyre Caitlin A, Zhang Haochen, Makohon-Moore Alvin P, Zucker Amanda, Wood Laura D, Myers Matthew A, Arnold Brian J, Zaccaria Simone, Chou Joanne F, Capanu Marinela, Socci Nicholas D, Raphael Benjamin J, Iacobuzio-Donahue Christine A
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Division of Gastrointestinal Pathology, Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland.
Cancer Discov. 2025 Feb 7;15(2):329-345. doi: 10.1158/2159-8290.CD-23-1541.
Although the pancreatic cancer genome has been described, it has not been explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify the genomic features of PDAC in the context of evolutionary metrics and in doing so have identified a novel prognostic biomarker.
尽管胰腺癌基因组已被描述,但尚未从诊断阶段或治疗瓶颈方面进行探索。我们现在在进化指标的背景下描述并量化了胰腺导管腺癌(PDAC)的基因组特征,在此过程中识别出了一种新的预后生物标志物。